Comparative Pharmacology
Head-to-head clinical analysis: PORTRAZZA versus VECTIBIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PORTRAZZA versus VECTIBIX.
PORTRAZZA vs VECTIBIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PORTRAZZA (necitumumab) is a recombinant human IgG1 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), thereby inhibiting ligand binding and subsequent activation of EGFR, leading to inhibition of downstream signaling pathways involved in cell proliferation and survival.
Epidermal growth factor receptor (EGFR) antagonist; binds to EGFR and competitively inhibits ligand binding, leading to inhibition of downstream signaling pathways including RAS/RAF/MAPK and PI3K/AKT, resulting in cell cycle arrest and apoptosis.
PORTRAZZA (necitumumab) is administered intravenously at a dose of 800 mg over 60 minutes on days 1 and 8 of each 21-day cycle.
6 mg/kg IV every 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 10–18 days). This long half-life supports dosing every 3 weeks and allows sustained receptor blockade.
Terminal half-life approximately 7.5 days (range 3.6–10.9 days); supports every-2-week dosing regimen.
Necitumumab is an IgG1 monoclonal antibody; elimination occurs via intracellular catabolism, with no significant renal or biliary excretion. No specific percentage of elimination via renal or fecal routes is established.
Primarily eliminated via the reticuloendothelial system; <3% excreted unchanged in urine; no significant renal or biliary elimination.
Category C
Category C
Antineoplastic Monoclonal Antibody
Antineoplastic Monoclonal Antibody